tirzepatide phase 3 study results Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, trial Tirzepatide Shows Superior Weight Loss

This research-grade compound is supplied as a lyophilised (freeze-dried) powder , ensuring stability and precision in controlled environments

PlexusDx semaglutide is compounded in licensed 503A pharmacies under strict pharmaceutical standards using the identical semaglutide active ingredient as Ozempic

The upcoming TRIUMPH-2 (type 2 diabetes) and TRIUMPH-3 (obesity + cardiovascular disease) results will provide more dysesthesia data across different patient populations and longer timeframes

Studies demonstrate keloids show upregulated p53-serine 15 phosphorylation (p53-pS15), identified through phosphospecific protein microarray and western blotting analysis

Ozempic is currently licensed in the UK for adults with type 2 diabetes mellitus who have inadequate glycaemic control despite lifestyle modifications, with or without other glucose-lowering medications

For a comprehensive breakdown of every documented side effect and what the TRIUMPH 4 data actually shows, see our full retatrutide side effects guide